Lysolecithin reprogramming via LPCAT1 modulation restores endothelial function and prevents diabetes-associated...

Area of Science:

• Biochemistry
• Metabolic Disorders
• Pharmacology

Background:

• Lysophosphatidylcholines (LPCs) and phosphatidylcholines (PCs) dysregulation is linked to endothelial dysfunction and impaired tissue repair.
• Organ-specific lysolecithin remodeling in type 2 diabetes (T2DM) remains poorly understood.
• This study investigates LPC/PC remodeling in a T2DM model and explores SP6, a peptide from Spirulina platensis, as a therapeutic.

Purpose of the Study:

• To elucidate the tissue-specific dynamics of LPC/PC remodeling in T2DM.
• To investigate the therapeutic potential of SP6 in modulating lipid metabolism and improving T2DM-related dysfunction.
• To identify key molecular mechanisms, including LPCAT1 and GLUT1, involved in T2DM pathogenesis and SP6's action.

Main Methods:

• LPC/PC levels analyzed by UHPLC-HRMS.
• Evaluated membrane fluidity, VEGF/API5, LPCAT1, VE-cadherin, and GLUT1 using various biochemical assays.
• In vivo studies involved inducing T2DM in mice, administering SP6, and assessing tissue lipidomics, GLUTs expression, and insulin secretion via MALDI-MS imaging.

Main Results:

• High glucose levels induced LPC/PC imbalance, increased membrane fluidity, and impaired wound healing by downregulating LPCAT1 and affecting GLUT1 translocation.
• SP6 administration in diabetic mice preserved LPCAT1 mRNA levels across multiple organs and selectively modulated plasma LPC species.
• SP6 improved glycemic control and insulin secretion in T2DM, linked to increased ATP production.

Conclusions:

• Tissue-specific lysolecithin reprogramming is identified as a key factor in T2DM development.
• LPCAT1-mediated lysolecithin remodeling is a mechanism underlying T2DM-related endothelial and metabolic dysfunction.
• SP6 demonstrates potential as a novel preventive treatment for T2DM by modulating lipid metabolism, vascular integrity, and glucose regulation.